MenACWY Vaccine
Meningococcal disease (serogroups A, C, W, Y) · Bacterial meningitis · Meningococcemia
Neisseria meningitidis causes two life-threatening presentations: meningitis (infection of the brain's protective membranes) and meningococcemia (blood infection). The disease's hallmark is its terrifying speed — a healthy teenager can be dead within 24 hours of first symptoms. Survivors face limb amputations, deafness, and cognitive impairment at high rates.
Overall Benefit Score
Default scenario · 12-month-old · US community (92% vax rate)
Score for your child →Worth careful consideration. Disease risk in your scenario is lower than average, or the vaccine risk/uncertainty is somewhat higher. Discuss timing and priorities with your provider.
📊 Evidence Scores
Scores computed from peer-reviewed data using VaxFact's evidence model. Based on default scenario (12-month-old, standard US community).
🦠 Disease Burden
Neisseria meningitidis causes two life-threatening presentations: meningitis (infection of the brain's protective membranes) and meningococcemia (blood infection). The disease's hallmark is its terrifying speed — a healthy teenager can be dead within 24 hours of first symptoms. Survivors face limb amputations, deafness, and cognitive impairment at high rates.
~10–15% of patients die despite antibiotics. Of survivors, ~20% suffer permanent sequelae: limb loss from tissue death (purpura fulminans), hearing loss, neurological damage, and skin scarring. The disease's psychological impact on families is severe — onset is so rapid that many never reach hospital in time.
🛡️ Vaccine Effectiveness
Antibody levels wane within 3–5 years, which is why a booster at age 16 is recommended for adolescents vaccinated at 11–12. Boosters are particularly important before college dormitory settings (peak risk factor).
Does not protect against serogroup B (MenB) — which requires a separate vaccine. Approximately 30–40% of US meningococcal disease in adolescents is now MenB, not covered by MenACWY.
⚠️ Adverse Events & Side Effects
All probabilities are per 100,000 doses administered, sourced from VAERS, Vaccine Safety Datalink, and post-licensure surveillance studies.
Common Side Effects
Rare Serious Events
📅 Vaccine Schedule
For unvaccinated older teens: 1 dose if 13–15 years, then booster at 16–18. College freshmen living in dorms: strongly consider vaccination if not previously vaccinated. Hajj pilgrims: required by Saudi Arabia.
⚖️ Benefits vs. Considerations
✓ Benefits
- Prevents a disease where 10–15% of patients die and 20% suffer permanent disability
- Disease moves so fast that vaccination is the only realistic prevention — antibiotics often arrive too late
- Critical for college dormitory settings where risk jumps significantly
- Well-established safety record over 20 years
- Required for Hajj pilgrimage — important for traveling families
↕ Considerations
- Very rare disease in absolute terms — exposure risk in average community is very low
- Does not cover serogroup B (requires separate MenB vaccine)
- Immunity wanes — booster required at age 16
- Cost-effectiveness is debated given low absolute disease incidence
🔬 What Some Researchers Question
These are legitimate scientific debates — not fringe claims. They represent areas of ongoing research or policy disagreement among credentialed experts.
- Health economists have questioned whether universal adolescent MenACWY vaccination is cost-effective given the low absolute incidence of meningococcal disease in the US (~300 cases/year total). Models suggest cost per quality-adjusted life year (QALY) saved may exceed standard cost-effectiveness thresholds, though the catastrophic nature of the disease complicates standard QALY analysis (Shepard et al., 2005).
- The shift in serogroup distribution — with MenB now accounting for 30–40% of adolescent cases not covered by MenACWY — suggests the vaccine program may be changing the epidemiology in ways that reduce its net coverage of the total disease burden over time.
🌫️ Scientific Uncertainties
Honest acknowledgment of what we don't yet know with confidence.
- Duration of antibody protection and optimal booster interval beyond current recommendations
- Whether mass vaccination has shifted serogroup distribution toward MenB (not covered)
- Cost-effectiveness compared with school-based outbreak response strategies
💉 Related Vaccines
Vaccines often given together or covering related diseases.
🌍 International Policy Comparison
How different countries approach this vaccine — revealing where global consensus is strong vs. where policy diverges.